Beeline Medicines

Leadership

Saqib Islam is Chief Executive Officer of Beeline Medicines, bringing more than 25 years of experience building and leading healthcare and life sciences companies to deliver life-changing medicines for patients. Mr. Islam previously served as Chief Executive Officer and a member of the Board of SpringWorks Therapeutics, where he built and led the company from its founding in 2017 through its evolution from a clinical-stage startup into a fully integrated, global, publicly traded commercial organization. Under his leadership, SpringWorks built a differentiated pipeline and commercial platform, and brought two novel, best-in-class therapies through global regulatory approvals and launches, with these medicines now serving patients living with devastating rare diseases around the world. His tenure at SpringWorks culminated in the company’s $3.9 billion acquisition by Merck KGaA, Darmstadt, Germany in 2025.

Prior to SpringWorks Therapeutics, Mr. Islam held executive leadership roles at Moderna Therapeutics and Alexion Pharmaceuticals, driving strategic growth and expanding global operations. Previously, Mr. Islam served in senior leadership positions in the global investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Boards of Beeline Medicines and ARS Pharmaceuticals.

He received his J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar, and bachelor’s degree from McGill University, graduating as a Faculty and University Scholar.

Dr. Badreddin Edris is President and Chief Operating Officer of Beeline Medicines and brings deep experience building and scaling biotechnology companies from drug discovery through commercialization. Most recently, he served as Chief Operating Officer of SpringWorks Therapeutics, where during his tenure, he played a central role in capital formation, strategic partnerships, operational scale-up, clinical development strategy, two global regulatory approvals and launches of category-leading medicines, and ultimately, the company’s sale to Merck KGaA, Darmstadt, Germany.

Previously, Dr. Edris was an investment professional on the private equity team at OrbiMed, where he focused on venture investments and company creation, including co-founding Silverback Therapeutics and Edgewise Therapeutics. Earlier in his career, he was a management consultant at Bain & Company, advising pharmaceutical and biotechnology companies. He currently serves on the Board of Edgewise Therapeutics and as a Venture Partner at The Column Group.

Dr. Edris received his Ph.D. in genetics from Stanford University School of Medicine, where he was an NSF research fellow.

Dr. Nathalie Franchimont is Chief Medical Officer of Beeline Medicines and brings more than 20 years of leadership experience in drug development across biotechnology and large pharmaceutical organizations. A physician-scientist by training, she has led programs spanning discovery research through early- and late-stage clinical development, global regulatory filings, and medical affairs across multiple therapeutic areas and modalities. Most recently, she served as Chief Medical Officer of Nimbus Therapeutics. Prior to Nimbus, Dr. Franchimont spent a decade at Biogen, where she last served as Senior Vice President and Head of the Multiple Sclerosis and Immunology Development Unit and held several other leadership roles across the research and development organization.

Earlier in her career, Dr. Franchimont held clinical development and medical affairs roles at Amgen. She currently serves on the Board of Directors of OMass Therapeutics.

Dr. Franchimont trained as a rheumatologist and received her M.D., Ph.D. from the University of Liège, Belgium and has conducted research at St. Francis Hospital/University of Connecticut School of Medicine, Yale University School of Medicine, and the University of Liège where she was also Chief of Clinic in Rheumatology.

Dr. Kristin Patterson is Chief Technical Operations Officer of Beeline Medicines and has more than 25 years of pharmaceutical and biotechnology experience with expertise in Chemistry, Manufacturing and Controls (CMC), regulatory affairs, supply chain logistics and commercial manufacturing. She previously served as Chief Technical Operations Officer at SpringWorks Therapeutics, where she built the CMC and Technical Operations functions and led the teams to FDA and EMA approvals and successful commercial launch of two novel, best-in-class therapies serving rare disease and oncology indications.

Prior to SpringWorks Therapeutics, Dr. Patterson held leadership roles at NephroGenex and Mycovia Pharmaceuticals and spent more than a decade at GSK, where she led global, cross-functional teams and provided CMC leadership to development programs from lead optimization to product registration and launch.

Dr. Patterson earned her Ph.D. in Chemistry from Stanford University and her bachelor’s degree from University of Illinois Urbana-Champaign.

Daniel Pichl is Chief People Officer at Beeline Medicines, where he leads the company’s people and culture strategy, overseeing organizational design, talent attraction and development, and total rewards. Most recently, he served as Chief People Officer at SpringWorks Therapeutics, where he played a key role in building and scaling the organization from a U.S.-based clinical-stage startup into a commercial-stage company with operations across multiple geographies.

Prior to SpringWorks, Mr. Pichl held senior human resources leadership roles at Siemens Healthineers, including Senior Vice President and Head of Human Resources for the company’s global ultrasound business. Earlier in his career, he held positions of increasing responsibility within Siemens, where he focused on culture and leadership development, organizational design, and global HR transformation initiatives.

Mr. Pichl holds a Master of international business from Macquarie University, Sydney, Australia, and a Master of psychology from Ludwig Maximilian University of Munich, Germany.